Projects per year
Personal profile
Biography
Chris Langmead has >25 years’ experience in pharmacology and neuroscience drug discovery across pharma (SmithKline Beecham; GlaxoSmithKline), biotech (Heptares Therapeutics), and academia (Monash University), and has worked on over 30 CNS programs, leading several from inception to clinical development. He is CEO and co-founder of Phrenix Therapeutics, and Chief Scientific Advisor and co-founder of Pacalis Therapeutics, both ventures focussed on the development of next-generation medicines in neuropsychiatry. He also holds a position as Research Professor in the Neuromedicines Discovery Centre (NDC) and the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University.
Monash teaching commitment
Associate supervision of HDR students in the Neuromedicines Discovery Centre and Drug Discovery Biology Theme.
Research interests
- Drug discovery and development
- Target validation
- Hit identification
- Lead optimisation
- Prelcinical development
- Clinical development
- Next-generation medicines for neuropsychiatric disorders
- GPCR pharmacology
- Molecular and analytical pharmacology
- Research translation and commercialisation
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- G protein-coupled receptors
- drug discovery
- hit identification
- high throughput screening
- muscarinic receptors
- neuropharmacology
- analytical pharmacology
- allosteric modulation
- structure-function
- target validation
- hit-to-lead
- lead optimisation
- psychiatric disorders
- cognitive disorders
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Drug Target Identification Platform
Creek, D. (Primary Chief Investigator (PCI)), Avery, V. M. (Chief Investigator (CI)), Pitson, S. M. (Chief Investigator (CI)), George, A. J. (Chief Investigator (CI)), Olechnowicz, S. (Chief Investigator (CI)), Baell, J. (Chief Investigator (CI)), Schittenhelm, R. (Chief Investigator (CI)), Li, J. (Chief Investigator (CI)), Langmead, C. (Chief Investigator (CI)), Stupple, P. (Chief Investigator (CI)), Drinkwater, C. (Chief Investigator (CI)), Flynn, B. (Chief Investigator (CI)), Brouwer, K. (Chief Investigator (CI)), Arndt, G. (Chief Investigator (CI)) & Newman, S. (Chief Investigator (CI))
Department of Health, Disability and Ageing (Australia)
30/06/23 → 6/12/28
Project: Research
-
Pre-clinical evaluation of selective adenosine A1 receptor positive allosteric modulators for the treatment of drug-resistant epilepsy
Kwan, P. (Primary Chief Investigator (PCI)), May, L. (Chief Investigator (CI)), Rollo, B. (Chief Investigator (CI)), O'Brien, T. (Chief Investigator (CI)), Casillas-Espinosa, P. (Chief Investigator (CI)), Howden, S. (Chief Investigator (CI)), Christopoulos, A. (Chief Investigator (CI)), Gregory, K. (Chief Investigator (CI)), Scammells, P. (Chief Investigator (CI)), Baltos, J.-A. (Chief Investigator (CI)), Elliott, D. (Chief Investigator (CI)), TN Nguyen, A. (Chief Investigator (CI)), Langmead, C. (Chief Investigator (CI)), Antonic-Baker, A. (Chief Investigator (CI)), Sumer, H. (Chief Investigator (CI)), Javaid, S. (Associate Investigator (AI)) & Gu, J. (Chief Investigator (CI))
1/06/22 → 31/05/27
Project: Research
-
Novel GPR52 agonists for schizophrenia / Phrenix Therapeutics
Stewart, G. (Primary Chief Investigator (PCI)), Langmead, C. (Chief Investigator (CI)), Nithianantharajah, J. (Chief Investigator (CI)) & Baell, J. (Chief Investigator (CI))
1/06/22 → …
Project: Research
-
To support the research and development of NHMRC guidelines on use of drugs for mental health conditions
Bell, S. (Primary Chief Investigator (PCI)), Langmead, C. (Chief Investigator (CI)), Lawrence, A. J. (Chief Investigator (CI)) & Davey, C. (Chief Investigator (CI))
1/02/24 → 31/01/25
Project: Research
-
Measuring attitudes towards using psychedelic drugs to treat mental illness
Kunstler, B. (Primary Chief Investigator (PCI)), Smith, L. (Chief Investigator (CI)), Wright, B. (Chief Investigator (CI)), Goodwin, D. (Chief Investigator (CI)), Hatty, M. (Chief Investigator (CI)) & Langmead, C. (Chief Investigator (CI))
27/10/22 → 25/11/22
Project: Research
-
Characterization of a putative orexin receptor in Ciona intestinalis sheds light on the evolution of the orexin/hypocretin system in chordates
Rinne, M. K., Urvas, L., Mandrika, I., Fridmanis, D., Riddy, D. M., Langmead, C. J., Kukkonen, J. P. & Xhaard, H., Dec 2024, In: Scientific Reports. 14, 1, 15 p., 7690.Research output: Contribution to journal › Article › Research › peer-review
Open Access2 Citations (Scopus) -
Ligand-directed biased agonism at human histamine H3 receptor isoforms across Gαi/o- and β-arrestin2-mediated pathways
Rahman, S. N., Imhaouran, F., Leurs, R., Christopoulos, A., Valant, C. & Langmead, C. J., Oct 2024, In: Biochemical Pharmacology. 228, 24 p., 115988.Research output: Contribution to journal › Article › Research › peer-review
Open Access4 Citations (Scopus) -
Molecular and structural insights into the 5-HT2C receptor as a therapeutic target for substance use disorders
Ubhayarathna, M., Langmead, C. J., Diepenhorst, N. A. & Stewart, G. D., Nov 2024, In: British Journal of Pharmacology. 181, 22, p. 4414-4429 16 p.Research output: Contribution to journal › Review Article › Research › peer-review
Open Access9 Citations (Scopus) -
Molecular insights into orphan G protein-coupled receptors relevant to schizophrenia
Lu, Y., Hatzipantelis, C. J., Langmead, C. J. & Stewart, G. D., Jul 2024, In: British Journal of Pharmacology. 181, 14, p. 2095-2113 19 p.Research output: Contribution to journal › Review Article › Research › peer-review
Open Access8 Citations (Scopus) -
Opportunities and challenges for the development of M1 muscarinic receptor positive allosteric modulators in the treatment for neurocognitive deficits
Nguyen, H. T. M., van der Westhuizen, E. T., Langmead, C. J., Tobin, A. B., Sexton, P. M., Christopoulos, A. & Valant, C., Jul 2024, In: British Journal of Pharmacology. 181, 14, p. 2114-2142 29 p.Research output: Contribution to journal › Review Article › Research › peer-review
15 Citations (Scopus)
Prizes
-
Georgina Sweet Fellowship
Lu, Y. (Recipient) & Langmead, C. (Recipient), 18 Jun 2021
Prize: Competitive Fellowships
Press/Media
-
How to boost community and stakeholder support for the use of psychedelic medicines
Kunstler, B., Hatty, M., Smith, L., Wright, B. & Langmead, C.
14/02/23
1 Media contribution
Press/Media: Article/Feature